MAY 29, 2014 07:30 AM PDT

Identification of predictive biomarkers from high throughput drug combination screening data

Speakers
  • Director, Translational Medicine, Thermo-Fisher Scientific
    Biography
      With Thermo Fisher Scientific, Dr. Bowden leads Pharma Client Services to provide custom bioinformatics solutions for oncology drug development and research. This group develops complete solutions from target discovery and validation, predictive biomarkers of response and drug combination synergies, to clinical testing hypotheses   Dr. Bowden has more than 18 years of research and leadership experience in cancer biology and drug development in both academic and industry settings. She has served as an Assistant Professor at Georgetown University. While in industry, Dr. Bowden led multiple preclinical projects and strategy area teams supporting the development of various types of biologic including antibodies, multispecifics and antibody-drug conjugates. She holds a PhD in Biochemistry from University of Bristol. 

    Abstract:

    One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding and overcoming tumor heterogeneity as well as inherent or emerging resistance are areas of significant ongoing research in both clinical and preclinical settings. Systematic approaches to support combination therapy clinical trial design are critical. Zalicus Inc. and Life Technologies have collaborated to develop a joint service offering that supports rationale design of cell line panels to inform and address the relevant genomic aberrations in disease subsequently enabling the identification of (1) potentially synergistic therapy combinations, (2) biomarkers of synergy, and (3) identification of potential clinical populations for hypothesis testing. During this segment, Dr. Bowden will discuss technical aspects of combination screening and biomarker discovery, major considerations required for success, provide examples of results, and offer potential impacts of this innovative service offering.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources